analysis,Reporting < 2 yrs,Summary results < 1 yr,Any results reporting
Main analysis,"1092/2113, 51.7% (95%CI 49.5-53.8%)","42/2113, 2% (95%CI 1.5-2.7%)","1638/2113, 77.5% (95%CI 75.7-79.2%)"
Only RCTs,"786/1516, 51.8% (95%CI 49.3-54.4%)","27/1516, 1.8% (95%CI 1.2-2.6%)","1172/1516, 77.3% (95%CI 75.1-79.3%)"
Restricted to EUCTR,"262/432, 60.6% (95%CI 56-65.1%)","29/432, 6.7% (95%CI 4.7-9.5%)","377/432, 87.3% (95%CI 83.8-90.1%)"
Restricted to ClinicalTrials.gov,"830/1681, 49.4% (95%CI 47-51.8%)","13/1681, 0.8% (95%CI 0.5-1.3%)","1261/1681, 75% (95%CI 72.9-77%)"
Exclude trials with unknown status,"968/1825, 53% (95%CI 50.7-55.3%)","42/1825, 2.3% (95%CI 1.7-3.1%)","1479/1825, 81% (95%CI 79.2-82.8%)"
Only completed trials,"928/1675, 55.4% (95%CI 53-57.8%)","37/1675, 2.2% (95%CI 1.6-3%)","1412/1675, 84.3% (95%CI 82.5-86%)"
Primary completion date,"947/2025, 46.8% (95%CI 44.6-48.9%)","34/2025, 1.7% (95%CI 1.2-2.3%)","1570/2025, 77.5% (95%CI 75.7-79.3%)"
Restricted to ClinicalTrials.gov with actual completion date,"711/1411, 50.4% (95%CI 47.8-53%)","13/1411, 0.9% (95%CI 0.5-1.6%)","1112/1411, 78.8% (95%CI 76.6-80.9%)"
